Novartis announced Wednesday that it upped its transparency initiative and that researchers will now be able to tap into patient-level data for drugs approved in the US and EU. The company also announced Wednesday that it was enhancing its Clinical Study Report summaries so the findings will be available in what the company described in a statement as “easy to understand consumer language” by the end of 2014.
Novartis said these summaries will also include “additional interpretation of data.”
The drugmaker is one of several companies that have touted their efforts to make data more accessible. Others include GlaxoSmithKline and J&J subsidiary Janssen.